HYPOTHERMIA AND HYPOGLYCEMIA INDUCED BY ANTI-CD3 MONOCLONAL-ANTIBODY IN MICE - ROLE OF TUMOR-NECROSIS-FACTOR

被引:99
作者
ALEGRE, M
VANDENABEELE, P
FLAMAND, V
MOSER, M
LEO, O
ABRAMOWICZ, D
URBAIN, J
FIERS, W
GOLDMAN, M
机构
[1] UNIV LIBRE BRUXELLES,PLURIDISCIPLINAIRE RECH EXPTL BIOMED LAB,B-1050 BRUSSELS,BELGIUM
[2] UNIV LIBRE BRUXELLES,PHYSIOL ANIM LAB,B-1050 BRUSSELS,BELGIUM
[3] STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM
关键词
D O I
10.1002/eji.1830200337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The possible involvement of tumor necrosis factor‐α (TNF) in the metabolic disturbances induced by anti‐CD3 monoclonal antibodies (mAb) was analyzed in DBA/2 mice injected with 50 μg of the anti‐murine CD3 mAb 145‐2C11. First, we found that 145‐2C11 induces a profound hypothermia maximal between 3 h and 6 h after the injection (at 3 h: − 3.0 ± 0.1 °C) as well as hypoglycemia (blood glucose levels at 6 h and 24 h: 76 ± 13 mg/100 ml and 92 ± 22 mg/100 ml, respectively, p < 0.001 as compared with control values). These metabolic changes are preceded by the release of TNF into the circulation (peak serum TNF levels at 2 h: 50 ± 23 pg/ml, p < 0.01 as compared with controls). The release of TNF induced by 145‐2C11 depends on the effect of the mAb on T cells as it is not observed in athymic nude mice while lipopolysaccharide‐resistant C3H/HeJ mice also display a significant rise in serum TNF (peak levels at 2 h: 59 ± 44 pg/ml). Pretreatment of DBA/2 mice with 12 mg of rabbit anti‐murine TNF antibodies completely prevents the hypothermia while the hypoglycemia is significantly attenuated. Finally, F(ab')2 fragments of 145‐2C11 induce only a transient hypoglycemia (blood glucose levels at 6 h: 109 ± 14, p < 0.001 as compared with controls) but neither hypothermia nor significant TNF release. We conclude that TNF is a major mediator of the acute metabolic changes induced by the intact form of 145‐2C11. Copyright © 1990 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim
引用
收藏
页码:707 / 710
页数:4
相关论文
共 21 条
[1]
RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL-ANTIBODY IN KIDNEY-TRANSPLANT RECIPIENTS [J].
ABRAMOWICZ, D ;
SCHANDENE, L ;
GOLDMAN, M ;
CRUSIAUX, A ;
VEREERSTRAETEN, P ;
DEPAUW, L ;
WYBRAN, J ;
KINNAERT, P ;
DUPONT, E ;
TOUSSAINT, C .
TRANSPLANTATION, 1989, 47 (04) :606-608
[2]
ABRAMOWICZ D, 1989, 7TH INT C IMM BERL
[3]
CONCOMITANT PRODUCTION OF DIFFERENT LYMPHOKINES IN ACTIVATED T-CELLS [J].
ANDERSSON, U ;
SANDER, B ;
ANDERSSON, J ;
MOLLER, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (12) :2081-2084
[4]
CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420
[5]
EVIDENCE OF INVOLVEMENT OF TUMOR NECROSIS FACTOR IN ADVERSE REACTIONS DURING TREATMENT OF KIDNEY ALLOGRAFT-REJECTION WITH ANTITHYMOCYTE GLOBULIN [J].
DEBETS, JMH ;
LEUNISSEN, KML ;
VANHOOFF, HJ ;
VANDERLINDEN, CJ ;
BUURMAN, WA .
TRANSPLANTATION, 1989, 47 (03) :487-492
[6]
ONE-MONTH PROPHYLACTIC USE OF OKT3 IN CADAVER KIDNEY-TRANSPLANT RECIPIENTS [J].
DEBURE, A ;
CHKOFF, N ;
CHATENOUD, L ;
LACOMBE, M ;
CAMPOS, H ;
NOEL, LH ;
GOLDSTEIN, G ;
BACH, JF ;
KREIS, H .
TRANSPLANTATION, 1988, 45 (03) :546-553
[7]
A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES [J].
ESPEVIK, T ;
NISSENMEYER, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) :99-105
[8]
THE EFFECTS OF TUMOR NECROSIS FACTOR AND THEIR SELECTIVE-INHIBITION BY IBUPROFEN [J].
EVANS, DA ;
JACOBS, DO ;
REVHAUG, A ;
WILMORE, DW .
ANNALS OF SURGERY, 1989, 209 (03) :312-321
[9]
HIRSCH R, 1988, J IMMUNOL, V140, P3766
[10]
HIRSCH R, 1989, J IMMUNOL, V142, P737